Vimian Group AB (publ) (VIMGF)
USD 3.5
(-14.29%)
USD 3.5
(-14.29%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 344.79 Million USD | 46.94% |
| 2022 | 234.65 Million USD | 14.77% |
| 2021 | 204.46 Million USD | 94.52% |
| 2020 | 105.11 Million USD | 505.26% |
| 2019 | 17.36 Million USD | 125.46% |
| 2018 | 7.7 Million EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 193.97 Million USD | -41.69% |
| 2024 Q3 | 240.12 Million USD | 38.15% |
| 2024 Q1 | 312.12 Million EUR | -0.53% |
| 2023 Q1 | 257.54 Million USD | 9.76% |
| 2023 Q4 | 344.79 Million USD | -2.63% |
| 2023 Q3 | 354.12 Million USD | -3.96% |
| 2023 Q2 | 368.72 Million USD | 43.17% |
| 2023 FY | 344.79 Million USD | 46.94% |
| 2022 Q4 | 234.65 Million USD | -18.93% |
| 2022 FY | 234.65 Million USD | 14.77% |
| 2022 Q3 | 289.42 Million USD | -12.1% |
| 2022 Q2 | 329.27 Million EUR | 0.44% |
| 2022 Q1 | 327.83 Million EUR | 60.34% |
| 2021 Q4 | 204.46 Million EUR | 37.1% |
| 2021 FY | 204.46 Million USD | 94.52% |
| 2021 Q2 | 151.91 Million EUR | 50.78% |
| 2021 Q3 | 149.13 Million EUR | -1.84% |
| 2021 Q1 | 100.75 Million EUR | 17.29% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 105.11 Million USD | 505.26% |
| 2020 Q4 | 85.9 Million EUR | 0.0% |
| 2019 FY | 17.36 Million USD | 125.46% |
| 2018 FY | 7.7 Million EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.24 Million USD | -15292.744% |
| Arrayit Corporation | 1.07 Million USD | -31879.968% |
| Atlantic International Corp. | 2.93 Million USD | -11665.876% |
| Biocept, Inc. | 12.1 Million USD | -2747.448% |
| Bioqual, Inc. | 3.58 Million USD | -9512.459% |
| CardioGenics Holdings Inc | 72.61 Thousand USD | -474736.069% |
| DermTech, Inc. | 54.39 Million USD | -533.889% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 471.86 Million USD | 26.929% |
| HTG Molecular Diagnostics, Inc. | 4.83 Million USD | -7032.834% |
| iMD Companies, Inc. | 1.12 Million USD | -30681.393% |
| IDenta Corp. | 789.14 Thousand USD | -43592.481% |
| Interpace Biosciences, Inc. | 11.19 Million USD | -2980.749% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 43.84 Thousand USD | -786300.874% |
| Lumos Diagnostics Holdings Limited | 8.04 Million USD | -4185.906% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 3.82 Million USD | -8912.216% |
| NovelStem International Corp. | 3.57 Million USD | -9545.766% |
| Optigenex Inc. | 8.94 Million USD | -3756.477% |
| PharmChem, Inc. | 77.35 Thousand USD | -445645.431% |
| Proteome Sciences plc | 17.15 Million USD | -1910.05% |
| Response Genetics, Inc | 6.37 Million USD | -5310.285% |
| Rennova Health, Inc. | 15.32 Million USD | -2149.264% |
| RushNet, Inc. | 4.82 Million USD | -7048.877% |
| ScreenPro Security Inc. | 207.03 Thousand USD | -166441.468% |
| Stella Diagnostics Inc. | 6.2 Million USD | -5460.635% |
| StageZero Life Sciences Ltd. | 1.8 Million USD | -19054.531% |
| Todos Medical Ltd. | 38.34 Million USD | -799.128% |